文献速递神经核医学肿瘤 PET/CT

FAP特异性PET/CT在IDH野生型胶质母细胞瘤及III/IV级IDH突变胶质瘤中示踪剂摄取升高

IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-08-06

本研究在体外分析FAPI-02与FAPI-04对成纤维细胞活化蛋白(FAP)的亲和力与特异性,并在小鼠体内评估药代动力学与生物分布,同时对18例胶质瘤患者(5例IDH突变、13例IDH野生型胶质母细胞瘤)行68Ga-FAPI-02/04 PET/CT。结果显示IDH野生型胶质母细胞瘤及III/IV级IDH突变胶质瘤摄取升高,而II级IDH突变胶质瘤未见升高,免疫组化可见FAP阳性细胞。

要点

  • IDH野生型胶质母细胞瘤和III/IV级IDH突变胶质瘤FAPI PET摄取升高,II级IDH突变者未见升高。
  • FAPI-04较FAPI-02在临床前研究中肿瘤聚集更高、清除更慢。
  • 胶质母细胞瘤中FAP阳性细胞主要为长胞体细胞及血管周围细胞。

核心结论

  • FAP特异性PET成像在IDH野生型胶质母细胞瘤和高grade IDH突变星形细胞瘤中示踪剂摄取升高,而在弥漫性星形细胞瘤中未见升高,可能有助于无创区分低级别IDH突变与高级别胶质瘤。

研究设计与样本

  • 体外结合研究使用177Lu标记的FAPI-02/04、U87MG胶质母细胞瘤细胞系、FAP转染纤维肉瘤细胞和CD26转染人胚胎肾细胞。
  • 临床前药代动力学与生物分布研究使用U87MG荷瘤小鼠注射68Ga标记化合物行小动物PET,以及177Lu标记FAPI-02/04。
  • 临床对18例胶质瘤患者(5例IDH突变胶质瘤、13例IDH野生型胶质母细胞瘤)静脉注射68Ga-FAPI-02/04后30分钟行PET/CT,并与MRI共配准。
  • 对14例胶质瘤用FAP特异性抗体行免疫组化。

主要发现

  • FAPI-02和FAPI-04对FAP显示高结合特异性。
  • 临床前研究中FAPI-04较FAPI-02肿瘤聚集更高、清除延迟。
  • IDH野生型胶质母细胞瘤和III/IV级IDH突变胶质瘤示踪剂摄取升高,II级IDH突变胶质瘤未见升高。
  • 胶质母细胞瘤中观察到投影于对比增强区域的摄取增高灶。
  • 免疫组化显示胶质母细胞瘤和间变性IDH突变星形细胞瘤中存在FAP阳性细胞,主要为长胞体细胞及血管周围FAP阳性细胞。

临床怎么用

  • FAP特异性PET成像或可用于胶质瘤随访研究,但需进一步临床评估。

局限性

  • 原文结论指出FAP特异性成像在胶质瘤中的应用仍需进一步临床评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Targeting fibroblast activation protein (FAP) is a new diagnostic approach allowing the visualization of tumor stroma. Here, we applied FAP-specific PET imaging to gliomas. We analyzed the target affinity and specificity of two FAP ligands (FAPI-02 and FAPI-04) in vitro, and the pharmacokinetics and biodistribution in mice in vivo. Clinically, we used 68Ga-labeled FAPI-02/04 for PET imaging in 18 glioma patients (five IDH-mutant gliomas, 13 IDH-wildtype glioblastomas). METHODS: For binding studies with 177Lu-radiolabeled FAPI-02/04, we used the glioblastoma cell line U87MG, FAP-transfected fibrosarcoma cells, and CD26-transfected human embryonic kidney cells. For pharmacokinetic and biodistribution studies, U87MG-xenografted mice were injected with 68Ga-labeled compounds followed by small-animal PET imaging and 177Lu-labeled FAPI-02/04, respectively. Clinical PET/CT scans were performed 30 min post intravenous administration of 68Ga-FAPI-02/04. PET and MRI scans were co-registrated. Immunohistochemistry was done on 14 gliomas using a FAP-specific antibody. RESULTS: FAPI-02 and FAPI-04 showed high binding specificity to FAP. FAPI-04 demonstrated higher tumor accumulation and delayed elimination compared with FAPI-02 in preclinical studies. IDH-wildtype glioblastomas and grade III/IV, but not grade II, IDH-mutant gliomas showed elevated tracer uptake. In glioblastomas, we observed spots with increased uptake in projection on contrast-enhancing areas. Immunohistochemistry showed FAP-positive cells with mainly elongated cell bodies and perivascular FAP-positive cells in glioblastomas and an anaplastic IDH-mutant astrocytoma. CONCLUSIONS: Using FAP-specific PET imaging, increased tracer uptake in IDH-wildtype glioblastomas and high-grade IDH-mutant astrocytomas, but not in diffuse astrocytomas, may allow non-invasive distinction between low-grade IDH-mutant and high-grade gliomas. Therefore, FAP-specific imaging in gliomas may be useful for follow-up studies although further clinical evaluation is required.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Röhrich M, Loktev A, Wefers AK, et al. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT. Eur J Nucl Med Mol Imaging. 2019. PMID: 31388723. doi:10.1007/s00259-019-04444-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。